Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides-Reference-Cited by-同舟云学术

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

Published:1995-08 Issue:3 Volume:58 Page:149-156
ISSN:0167-0115
Container-title:Regulatory Peptides
language:en
Short-container-title:Regulatory Peptides

Author:

Hupe-Sodmann Karin,McGregor Gerard Patrick,Bridenbaugh Robert,Göke Rüdiger,Göke Burkhard,Thole Hubert,Zimmermann Bodo,Voigt Karlheinz

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Clinical Biochemistry,Endocrinology,Physiology,Biochemistry

Reference23 articles.

1. Glucagon-like peptide-1, a new hormone of the entero-insular axis;Orskov;Diabetologia,1992

2. Insulinotropic glucagon-like peptide-1 (7–37)/(7–36)amide: a new incretin hormone;Fehman;Trends Endocrinol. Metab.,1992

3. Antidiabetic effect of glucagon-like peptide-1(7–36)amide in normal subjects and patients with diabetes mellitus;Gutniak;N. Engl. J. Med.,1992

4. Normalization of fasting hyperglycaemia by exogenous GLP-1(7–36)amide in type 2-diabetic patients;Nauck;Diabetologia,1993

5. Cell surface peptidases are neither peptide or organ specific;Kenny;Trends Biochem. Sci.,1986

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for CombatingAlzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review;Current Topics in Medicinal Chemistry;2024-07

2. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07

3. Gut-specific Neprilysin Deletion Protects Against Fat-induced Insulin Secretory Dysfunction in Male Mice;Endocrinology;2024-07-01

4. Novel Angiogenesis Role of GLP-1(32–36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R–Dependent Glycolysis in Mice;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-03-21

5. Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy;iScience;2023-11